Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
You can also access detailed information by clicking Login in the website header.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
USA
Regulatory Approval:
Your Trustedworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Rybrevant (amivantamab-vmjw) is a bispecific antibody that simultaneously targets EGFR and MET receptors, used across several EGFR-mutated non-small cell lung cancer (NSCLC) settings, often in combination with other targeted or chemotherapy agents. It is used together with Lazcluze (lazertinib) for the first-line, chemotherapy-free regimen.
Rybrevant, combined with lazertinib, is FDA-approved as first-line treatment for locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations. Combined with carboplatin and pemetrexed, it is approved as first-line treatment for EGFR exon 20 insertion-mutated NSCLC. As a single agent, it is approved for EGFR exon 20 insertion-mutated NSCLC after progression on platinum-based chemotherapy.
Amivantamab binds both EGFR and MET receptors, blocking their signaling and marking tumor cells for immune-mediated destruction, addressing resistance mechanisms that limit single-target EGFR inhibitors.
Dosing is based on body weight, administered intravenously on a defined weekly-then-biweekly schedule (loading doses in the first weeks, followed by maintenance dosing), in combination with lazertinib or chemotherapy per the specific indication, as determined by the treating oncologist.
Rybrevant requires close monitoring for several important safety considerations.
Severe skin rash, including toxic epidermal necrolysis and acneiform dermatitis, can occur. Prophylactic and concomitant skin-directed medications are typically recommended from treatment initiation.
Infusion reactions, including anaphylaxis, most often occur with the first infusion. Premedication and close monitoring during infusion are standard practice.
Increased risk when combined with lazertinib, particularly in the first 4 months. Anticoagulant prophylaxis is commonly used during this period.
Monitor for new or worsening respiratory symptoms.
Monitor for visual changes and refer to ophthalmology as needed.
Rybrevant can cause fetal harm. Effective contraception is required during treatment and for a defined period after the final dose.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
Rybrevant (amivantamab-vmjw) is manufactured by Janssen Biotech and is used across multiple EGFR-mutated NSCLC settings, often together with Lazcluze (lazertinib).
Import of Rybrevant through a Named Patient Program requires a valid prescription from the treating oncologist, confirmation of EGFR mutation status via an FDA-approved test, and supporting clinical documentation as required by Indian regulatory authorities.
NPP sources Rybrevant directly from Janssen's authorized supply chain to ensure product authenticity and regulatory compliance.
Rybrevant is sourced through verified, GDP-compliant, cold-chain channels from Janssen's authorized supply chain to ensure authenticity and quality.
Rybrevant should be stored refrigerated at 2°C to 8°C, in the original carton to protect from light. Do not freeze.
Once sourced, Rybrevant is packed and transported under continuous cold-chain conditions to preserve product integrity throughout the import process, with tracking and updates provided at each stage of delivery to the patient or treating hospital in India.
Patients across India can access Rybrevant through NPP's regulated import pathway, with oncology specialists in major cities supporting the treatment process.
Leading oncology centers in Mumbai support EGFR mutation testing and treatment coordination for Rybrevant access.
Delhi's major cancer hospitals assist patients with molecular testing and prescription support for Rybrevant.
Bangalore's oncology network offers access to EGFR testing and treatment planning for eligible NSCLC patients.
Chennai-based specialists coordinate Rybrevant access alongside comprehensive lung cancer care.
Hyderabad's cancer care institutions support patients pursuing Rybrevant therapy following confirmed EGFR mutation status.
Kolkata's oncology centers help coordinate documentation and treatment access for Rybrevant.
Pune-based oncologists assist with EGFR mutation testing and Rybrevant treatment planning.
Ahmedabad's specialty hospitals support the import and treatment process for Rybrevant.
Kochi's oncology units assist patients with the documentation needed for Rybrevant access.
Chandigarh's cancer care centers support Rybrevant treatment coordination for patients from North India.
Jaipur's oncology specialists help patients navigate the Rybrevant access process.
Lucknow-based cancer centers assist patients pursuing Rybrevant therapy.
Bhubaneswar's oncology institutions support access to Rybrevant for eligible patients.
Guwahati's specialists help coordinate Rybrevant access for patients across the Northeast.
Patients in other cities across India can also access Rybrevant through NPP's nationwide coordination network.
Written By: Nitin Goswami, Senior Medical Content Writer
Last Updated: 10 September 2026
Sources: FDA • CDSCO
Medically Reviewed By: Shilpi Banerjee, Registered Pharmacist (M.Pharm)
Last Updated: 10 September 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
